Cite
HARVARD Citation
Sartore-Bianchi, A. et al. (n.d.). Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet oncology. 17 (6), pp. 738-746. [Online].